Dianthus Therapeutics, Inc.
DNTH
$115.96
$6.365.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.97% | 36.62% | -75.25% | -16.24% | -7.18% |
| Total Depreciation and Amortization | 40.79% | -21.65% | -2.02% | 0.00% | -25.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.62% | 98.89% | 49.57% | -29.00% | 34.45% |
| Change in Net Operating Assets | -326.17% | -82.25% | 337.20% | -6.45% | 283.52% |
| Cash from Operations | -69.74% | 38.58% | -53.77% | -27.89% | 13.53% |
| Capital Expenditure | -1,710.00% | 92.75% | -2,660.00% | 89.13% | -91.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -257.07% | -458.76% | 118.55% | -859.77% | 78.78% |
| Cash from Investing | -257.17% | -460.11% | 118.48% | -861.11% | 78.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.57% | 14,496.12% | -98.15% | 48,260.04% | 252.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.03% | -599.48% | -11.63% | -- | -- |
| Cash from Financing | -98.60% | 15,042.54% | -98.22% | 48,229.75% | 252.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.69% | 11,874.17% | -111.47% | 1,267.61% | 124.62% |